CD3-δ Inhibitors
The class of CD3-δ inhibitors comprises a diverse set of compounds that effectively modulate T-cell activation by targeting key signaling pathways. These inhibitors exert their effects either directly on CD3-δ or indirectly through interference with downstream cascades crucial for T-cell function. Cyclosporin A and Tacrolimus, both calcineurin inhibitors, disrupt the calcineurin-NFAT signaling axis, indirectly inhibiting CD3-δ-mediated pathways. Mycophenolic Acid, a selective IMPDH inhibitor, interferes with de novo purine synthesis, indirectly suppressing CD3-δ-related signaling events.
Rapamycin, Fingolimod, and Sirolimus act indirectly by inhibiting mTOR, a central regulator in T-cell activation pathways. These compounds, forming complexes with FKBP12, disrupt mTOR-dependent processes, leading to the indirect inhibition of CD3-δ-mediated signaling. Fingolimod, additionally, modulates sphingosine-1-phosphate receptors to influence T-cell trafficking. Calcineurin Autoinhibitory Peptide mimics the autoinhibitory domain of calcineurin, competitively binding to inhibit its activity and indirectly suppressing CD3-δ-related events. U73122, a PLC inhibitor, and Pimecrolimus, a calcineurin inhibitor, target early events in T-cell receptor signaling, leading to the indirect inhibition of CD3-δ. CNI-1493 interferes with NF-κB activation by inhibiting IKKβ, providing an indirect mechanism to suppress CD3-δ-mediated pathways. Sirolimus, Tofacitinib, and IMD 0354 further broaden the spectrum of CD3-δ inhibitors by targeting mTOR, JAKs, and IKKβ, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits CD3-δ indirectly by interfering with the calcineurin-NFAT signaling pathway. It forms a complex with cyclophilin, which, in turn, inhibits calcineurin. This disruption prevents the dephosphorylation and nuclear translocation of NFAT, thereby suppressing T-cell activation and indirectly inhibiting CD3-δ-mediated signaling. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Tacrolimus acts as an indirect inhibitor of CD3-δ by binding to FKBP12, forming a complex that inhibits calcineurin. The inhibition of calcineurin disrupts the activation of NFAT, preventing its translocation to the nucleus. This interference in the calcineurin-NFAT signaling axis results in the suppression of T-cell activation and, consequently, indirect inhibition of CD3-δ-mediated pathways. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid inhibits CD3-δ indirectly by interfering with the de novo synthesis of guanine nucleotides. It specifically targets inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo purine synthesis pathway. By inhibiting IMPDH, mycophenolic acid disrupts T-cell proliferation, leading to the indirect inhibition of CD3-δ-mediated signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin indirectly inhibits CD3-δ by forming a complex with FKBP12, which in turn inhibits mTOR (mammalian target of rapamycin). Inhibition of mTOR disrupts the downstream signaling pathways crucial for T-cell activation and effector function, indirectly suppressing CD3-δ-mediated signaling. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Fingolimod inhibits CD3-δ indirectly by acting as a sphingosine-1-phosphate (S1P) receptor modulator. By internalizing S1P receptors on T cells, it prevents their egress from lymph nodes, leading to a reduction in circulating T cells and the subsequent indirect inhibition of CD3-δ-mediated signaling events. | ||||||
Pimecrolimus | 137071-32-0 | sc-208172 | 1 mg | $140.00 | 2 | |
Pimecrolimus indirectly inhibits CD3-δ by acting as a calcineurin inhibitor. Similar to tacrolimus, it forms a complex with FKBP12, inhibiting calcineurin and disrupting the calcineurin-NFAT signaling axis. This interference prevents NFAT translocation to the nucleus, resulting in the indirect inhibition of CD3-δ-mediated T-cell activation. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD 0354 inhibits CD3-δ indirectly by targeting IKKβ, a key regulator of the NF-κB pathway. By blocking IKKβ activity, it disrupts the canonical NF-κB pathway, leading to the indirect inhibition of CD3-δ-mediated T-cell activation. | ||||||